Lung Cancer Clinical Roundup

News Articles

(ESMO) Aug 11, 2020 - The NCI-MATCH Trial Subprotocol H (EAY131-H) met its primary endpoint with the response rate of 37.9% and high rate of disease control in the mixed histology, pretreated cohort.
(2020 IASLC Virtual) Aug 10, 2020 - The randomized phase III CheckMate 743 trial breaks new ground in malignant pleural mesothelioma (MPM) by establishing the benefit of a chemotherapy-free regimen in patients with previously untreated disease.
(Pharmaphorum [UK]) Aug 10, 2020 - Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, getting one up over rival checkpoint inhibitor Keytruda from Merck & Co. The results of the CheckMate-743 trial showed that a combination of Opdivo (nivolumab) with...
(BMS) Aug 8, 2020 - CheckMate -743 is the first and only Phase 3 trial in which first-line immunotherapy treatment improved survival in patients with malignant pleural mesothelioma. With these positive results, Opdivo plus Yervoy has now shown clinical benefit in six different tumor types, including durable, superior overall survival...
View all lung (includes nsclc, sclc, mesothelioma) cancer news

Podcasts

podcastImage
Roy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients
podcastImage
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

News Commentary

Editor Image
Better than chemo. Just not better than the current standards of immunotherapy...
Editor Image
In my opinion, these data should be practice changing for the subset of...
Editor Image
An unsurprising result, with lorlatinib clearly a more effective ALK inhibitor...

Featured Lung (includes NSCLC, SCLC, Mesothelioma) Cancer Tweets

David R. Gandara, MD
drgandara - Aug 10  Reimbursement tied to # of genes tested in molecular panel? Have not heard that one in a few years. Certainly not i… https://t.co/rRGXsDMK9m

Suresh S. Ramalingam, MD
RamalingamMD - Aug 08  Checkmate 743 demonstrates superiority for Ipi plus nivo over chemo in mesothelioma. Hazard ratio 0.75. @IASLChttps://t.co/lvIQCALvs4

Suresh S. Ramalingam, MD
RamalingamMD - Aug 08  Ensartinib joins the ‘leader pack’ for 1st line Tx of ALK+ NSCLC. Congrats @HornLeora @IASLC #VPS20 @christine_lovly .